Rationale: Mitochondrial dysfunction plays a pivotal role in the development of heart failure. Animal studies suggest that impaired mitochondrial biogenesis attributable to downregulation of the peroxisome proliferator-activated receptor ␥ coactivator (PGC)-1 transcriptional pathway is integral of mitochondrial dysfunction in heart failure. Objective: The study sought to define mechanisms underlying the impaired mitochondrial biogenesis and function in human heart failure. Methods and Results: We collected left ventricular tissue from end-stage heart failure patients and from nonfailing hearts (n‫,32؍‬ and 19, respectively). The mitochondrial DNA (mtDNA) content was decreased by >40% in the failing hearts, after normalization for a moderate decrease in citrate synthase activity (P<0.05). This was accompanied by reductions in mtDNA-encoded proteins (by 25% to 80%) at both mRNA and protein level (P<0.05). The mRNA levels of PGC-1␣/␤ and PRC (PGC-1-related coactivator) were unchanged, whereas PGC-1␣ protein increased by 58% in the failing hearts. Among the PGC-1 coactivating targets, the expression of estrogen-related receptor ␣ and its downstream genes decreased by up to 50% (P<0.05), whereas peroxisome proliferator-activated receptor ␣ and its downstream gene expression were unchanged in the failing hearts. The formation of D-loop in the mtDNA was normal but D-loop extension, which dictates the replication process of mtDNA, was decreased by 75% in the failing hearts. Furthermore, DNA oxidative damage was increased by 50% in the failing hearts. Conclusions: Mitochondrial biogenesis is severely impaired as evidenced by reduced mtDNA replication and depletion of mtDNA in the human failing heart. These defects are independent of the downregulation of the PGC-1 expression suggesting novel mechanisms for mitochondrial dysfunction in heart failure. (Circ Res. 2010;106:1541-1548.)
M itochondrial dysfunction has been observed in a variety of cardiac diseases, including myocardial ischemia, diabetic cardiomyopathy and heart failure. Accumulating evidence have suggested that mitochondrial dysfunction accounts for impaired myocardial energetics and increased cell death during myocardial injury and the development of heart failure. 1, 2 However, the molecular mechanisms responsible for the mitochondrial dysfunction under these pathological conditions are poorly understood making it difficult to develop mitochondriatargeted therapy.
Recent studies have revealed a central role of peroxisome proliferator-activated receptor ␥ coactivator (PGC)-1 family proteins in mitochondrial biogenesis and function in multiple organs including the heart. [3] [4] [5] Downregulation of PGC-1␣ and its target genes have been observed in a number of rodent models of heart failure raising the intriguing possibility that impaired mitochondrial biogenesis can be a causal mechanism for mitochondrial dysfunction in heart failure. 6, 7 How-ever, despite strong evidence suggesting a critical role of PGC-1 mediated mitochondrial biogenesis for normal cardiac function in animal models 6, 8, 9 changes of mitochondrial biogenesis in human heart failure have not been fully characterized, and the regulatory mechanisms not understood. PGC-1 coactivates a number of transcriptional factors involved in mitochondrial biogenesis, eg, peroxisome proliferator-activated receptors (PPARs), estrogen-related receptors (ERRs), and nuclear respiratory factors (NRFs). The respective role of each of these pathways has not been defined in human heart failure.
In this study, therefore, we sought to determine whether defective mitochondrial biogenesis was characteristic of human failing heart, and if so, whether PGC-1 mediated transcriptional cascade plays a role. Our results showed that mitochondrial DNA (mtDNA) content as well as the expression of mtDNA-encoded proteins were markedly decreased in the human failing heart. Furthermore, we have identified defects in mtDNA replication and maintenance in the failing heart that were independent of the PGC-1 level but were associated with downregulation of ERR␣ and increased oxidative DNA damage.
Methods

Myocardial Samples From Nonfailing and Failing Hearts
The failing heart samples (HF) (nϭ23) were obtained from the left ventricular (LV) free wall or apex of the heart during heart transplantation or implantation of a LV assist device. The nonfailing heart samples (NF) (nϭ19) were obtained from the LV free wall of donor hearts found unsuitable for transplantation for a variety of reasons eg, history of blood transfusion in the emergency room, unacceptable age, or history of resuscitation before death etc. All donors had no history, macroscopic, or laboratory signs of cardiac diseases. The local ethics committee approved the study protocol.
RNA Isolation and Real Time PCR
Total RNA was isolated from frozen LV tissue using the RNeasy Kit (Qiagen), and cDNA was synthesized using Omniscript reverse synthase and random hexamers according to manufactures guidelines. Real Time PCR was performed using SYBR green (Bio-Rad). The primers are described in Online Table I , available in the Online Data Supplement at http://circres.ahajournals.org. The Real Time PCR results for the mRNA levels of each gene were normalized to 18S rRNA levels.
Immunoblot Analysis
Frozen myocardial tissue from LV was homogenized with the RIPA lysis buffer, and 50 g of proteins per sample were separated by SDS-PAGE. The protein levels for human TFAM (ab47517), transcription factor (TF)B2M (ab66014), GAPDH (ab9485), ERR␣ (ab76228), ERR␥ (ab82319), ND6 (ab81212), flavoprotein (SDHA; MS204), cyclophilin D (CYPD; MSA04), cytochrome b (CYTB) (sc11436), and NADH dehydrogenase (ND)1 (H00004535-A01) were detected using commercial antibodies from Abcam, Mitosciences, Santa Cruz Biotechnology, and Abnova. Several antibodies against PGC-1␣ were tested using heart tissue from PGC-1␣-null or PGC-1␣ overexpression mice (kindly provided by Dr Zoltan Arany, Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, Mass). Results presented here were obtained using the PGC-1␣ antibody from Calbiochem (ST1202) that demonstrated appropriate sensitivity and specificity against both mouse and human PGC-1␣ protein.
Measurements of Enzyme Activity, mtDNA Content, and mtDNA Replication
Citrate synthase (CS) activity was measured in tissue homogenate as previously described. 10 The content of mtDNA was determined by Real Time PCR using primers amplifying the 16S and cytochrome c oxidase subunit I (COI) region, and was normalized to that of 18S in nDNA. The RNA-DNA hybrid region (7S DNA) that initiated the mitochondrial D-loop formation was measured in the RNA extracts (free of DNA contamination) using Real Time PCR. 11 To assess the replication of mtDNA, we quantified single stranded DNA generated from the extension of the 7S DNA in the D-loop region, a committed step in mtDNA replication. 11, 12 This was achieved by treating the DNA preparation with Mnl I endonuclease that selectively digested double stranded DNA in the presence of Mn 2ϩ at its target sequence: 5Ј-CCTC(N)7^-3 13 followed by real-time PCR with primers that spanned 185bp segment in the CYTB region (proximal to D-Loop, and contains 2 distinct sites of MnlI). We found that MnlI cleaved the doubled stranded DNA region of CYTB with Ͼ99.9% efficiency under our experimental conditions while leaving a segment of COI region devoid of 5Ј-CCTC(N)7^-3 sequence totally intact. Thus, the ratio of the PCR products amplifying the CYTB and the COI regions after the Mnl I treatment reflected the fractional amount of mtDNA in replication.
8-Hydroxydeoxyguanosin Assay
Genomic DNA was isolated from LV tissue using the DNeasy Tissue Kit (Qiagen) in the presence of the free radical spin trap phenyl-tertbutyl nitrone (50 mmol/L, Sigma). All assay buffers were purged with N 2 to prevent in vitro oxidation of the DNA. Approximately 300 ng of genomic DNA was used for 8-hydroxydeoxyguanosin (8-OH-dG) measurements using a commercially available kit from Cayman according to the instructions of the manufacturer.
Statistical Analysis
Comparisons among the groups were performed by 1-way ANOVA, followed by Tukey's post hoc comparisons. Pearson's correlation coefficients were computed to determine the correlation between mRNA and mtDNA or the mRNA level. All analyses were performed using GraphPad Prism 4.0. All data are expressed as meanϮSEM and a PՅ0.05 was considered significant. Data are shown as meansϮSEM unless indicated otherwise. PWP indicates pulmonary wedge pressure. similar for the NF and HF groups. Approximately 1/3 of the HF patients had ischemic heart diseases. Table 2 shows the clinical characteristics in the ischemic versus nonischemic heart failure subgroups recorded one week before the sample collection. The inotropic treatment was used extensively in both the nonischemic (100%) and the ischemic heart failure (78%) patients, whereas more ischemic patients received statin treatment. Despite the different etiologies of heart failure, no significant differences in the results presented here were observed between the end-stage nonischemic and ischemic HF samples. The mRNA levels of heart failure marker genes brain natriuretic peptide and SERCA2 (sarco-/endoplasmic reticulum calcium ATPase 2, mitochondrial) were determined in all samples ( Figure 1 ). Consistent with previous reports, significant upregulation of brain natriuretic peptide and downregulation of SERCA2 were observed in HF ( Figure 1A and 1B).
Results
General Characteristics
Mitochondrial Biogenesis Is Impaired in Heart Failure
To determine whether human heart failure was associated with changes in the total mitochondria volume mass, we assessed a variety of mitochondrial markers at the levels of enzyme activity, protein expression and mtDNA content. The activity of citrate synthase, a key enzyme in the Krebs cycle and a widely used marker for mitochondrial matrix proteins, was decreased by Ϸ25% in HF samples (Figure 2A ). The inner mitochondrial membrane protein CYPD was only reduced by Ϸ10% in HF and the Complex II protein SDHA, encoded by the nDNA, was not different between the groups ( Figure 2C and 2D) . In contrast, the Complex I and III proteins ND1, ND6 and CYTB, encoded by the mtDNA, were markedly reduced in HF ( Figure 2C and 2D ). Furthermore, we detected a 57% reduction of mtDNA (normalized by nDNA) in the failing samples ( Figure 2B ). Note that the reduction of the mtDNA copy number was more than 2-fold greater than the decreases in mitochondrial enzyme activity or nDNA encoded mitochondrial proteins. These findings indicated a greater reduction of mtDNA content than that of mitochondria mass in the failing hearts. To rule out the possibility that relative increases of the noncardiomyocyte population in the failing hearts might have "diluted" the average mitochondria amount per nucleus in the myocardium, mtDNA was also normalized to citrate synthase activity. The mtDNA/citrate synthase activity remained 43% lower in HF samples compared to NF heart samples (Online Figure I, A) . Additionally, there was no significant change in the expression of the fibroblast marker DDR2 (Discoidin domain receptor 2) or in the total nDNA content normalized to the total protein content (Online Figure I, B and C). Taken together, these results showed that mtDNA content and mtDNA-encoded proteins were significantly reduced in human failing heart, indicative of impaired mitochondrial biogenesis.
PGC-1 Is Maintained Whereas ERR␣ Is Downregulated in Human Failing Heart
The evidence of reduced mtDNA and proteins prompted us to assess the PGC-1 transcriptional cascade in the human failing heart. In contrast to the previous observations in animal models, we found that the mRNA levels of the 3 members of the PGC-1 family (PGC-1␣, PGC-1␤ and PGC-1-related coactivator [PRC]) were not altered in human failing hearts ( Figure 3A ). Despite the unremarkable changes in the mRNA expression of the PGC-1 family, the PGC-1␣ protein was increased by 58% in human HF ( Figure 3B ). This finding was unlikely attributable to the differences in the time duration between heart excision and tissue freezing for the two groups, as we observed no change in the mRNA and protein levels of PGC-1␣ in mouse and human hearts kept in the cold preservation solution for up to 12 hours (Online Figure II) .
Among the transcriptional factors PGC-1 coactivates in mitochondrial biogenesis, there was no change in the expressions of PPAR␣, NRF1 and NRF2A but there was a significant reduction in the expression of ERR␣ in the failing hearts at the mRNA as well as at the protein level ( Figure 3A and 3B). ERR␥, another member of the ERR family, decreased modestly at mRNA level (Ϸ25%, PϭNS) but did not change at the protein level. Furthermore, there was also a slight but significant decrease in the mRNA and protein of TFAM ( Figure 3B and 3C) which is an important protein for the mtDNA maintenance. The expression of the partner of TFAM, TFB2M, was reduced at the mRNA but not at the protein level ( Figure 3B and 3C) .
To assess the functional significance of the changes in the PGC-1 proteins as well as its coactivating targets we measured the expressions of their downstream genes involved in mitochondrial biogenesis. The expression of genes that were under the control of both PPAR␣ and ERR␣ did not change significantly but the expression of genes that were predominantly under the control of ERR␣ alone was significantly reduced in the failing group ( Figure 3C ). Note that the expression of mtDNA-encoded genes that are indirect targets of ERR␣ was further reduced. In addition, there was a strong correlation between the mtDNA content and the mRNA levels of mtDNA-encoded proteins (Figure 4) . Regression analysis revealed a curvilinear relationship between the mtDNA and COI mRNA (rϭ0.71) or ATP synthase 6 mRNA (rϭ0.76). These results suggested that the coactivation function of the PGC-1 was sustained in human failing hearts. Although downregulation of ERR␣ likely contributed to the decreased transcription of a selection of nuclear-encoded mitochondrial proteins, the depletion of mtDNA played a critical role in the decreased expression of the mtDNAencoded proteins in the failing hearts.
Impaired DNA Replication Leads to mtDNA Depletion
To investigate the mechanism(s) that accounts for reduced mtDNA, we tested whether mtDNA replication was impaired in the failing heart. We examined two major steps in the mtDNA replication: the formation and the extension of the D-loop region. The synthesis of 7S DNA in the D-Loop region was proportional to the abundance of mtDNA in the failing hearts compared to the nonfailing controls ( Figure 5A ). This result suggested that a similar fraction of mtDNA formed D-loop in the failing versus nonfailing hearts. In support of this, the expression of the single strand DNA binding protein (mtSSBP1) was unaltered in the failing hearts ( Figure 5C ). Because the formation of the D-loop was initiated by the synthesis of RNA, 14 this finding was consistent with our observation that the transcription of the mitochondrial genome was intact. In contrast, the extension of 7S DNA beyond the D-Loop region (indicative of DNA replication in progress) was substantially reduced in the failing hearts. We found that the amount of single strand DNA extended immediately beyond the D-loop was decreased by 75% per mtDNA copy ( Figure 5B ). We also observed that the expressions of proteins in the DNA replication complex, ie, polymerase ␥ (POLG), polymerase ␥ accessory subunit (POLG2), PEO1 (progressive external ophthalmoplegia 1), and topoisomerase I were significant downregulated in the failing hearts ( Figure 5C ). These results suggested that mechanism(s) involved in the extension of DNA strand rather than the initiation of mtDNA replication was defective in the human failing heart.
Another possible cause of impaired DNA replication and mtDNA depletion in the failing heart is increased DNA damage attributable to a greater oxidative stress. [15] [16] [17] DNA oxidation by reactive oxygen radicals occurs most readily at guanine residues to form 8-OH-dG because of the high oxidation potential of this base. We found that the levels of 8-OH-dG in the DNA were Ϸ50% higher in the failing hearts ( Figure 6 ), suggesting an increased oxidative DNA damage in the failing heart.
Discussion
Our results demonstrate that significant decreases in the expression of mtDNA-encoded proteins in human failing hearts are attributable to mtDNA depletion rather than decreased transcriptional activity of the mitochondrial genome. Furthermore, we have identified defects in mtDNA replication and maintenance in the failing heart that are independent of the PGC-1 level but are associated with downregulation of ERR␣ and increased oxidative DNA damage. These observations suggest novel mechanisms for impaired mitochondrial biogenesis and provide an important basis for the future development of mitochondria-targeted therapy for heart failure.
Mitochondrial Dysfunction and mtDNA Depletion in Heart Failure
Mitochondrial dysfunction has been repeatedly observed in the failing hearts of animal models and patients but its underlying mechanisms are poorly understood. There has been increasing evidence of impaired mitochondrial biogenesis in animal models of heart failure. 6, 7, 18, 19 The present study shows that mtDNA content and replication are markedly decreased in human failing hearts, resulting in lower expression of mtDNA-encoded proteins. Previous studies have demonstrated that quantitative and/or qualitative defects of mtDNA lead to mitochondrial dysfunction, cardiomyopathy and heart failure. 15,20 -23 Mouse models of mitochondrial gene knockout have not been reported, but more than 50% of disease mutations in mtDNA cause cardiomyopathy suggesting an essential role of mtDNA-encoded proteins in mitochondrial function of the heart. 24 Additionally, chemotherapy drugs that inhibit DNA replication, such as doxorubicin or the NRTIs (nucleoside-transcriptase inhibitors), deplete mtDNA and cause cardiac toxicity. 20, 21, 25 Conversely, overexpression of human TFAM in mouse hearts maintains high levels of mtDNA post myocardial infarction and significantly delays the development of heart failure. 26 Because human TFAM lacks transcriptional activity in mouse mitochondrial genome, this study suggests that the maintenance of mtDNA level plays an independent role in protecting against the heart failure. 26 Thus, results of the present study add to the growing evidence suggesting that depletion of mtDNA is an important aspect of the biological defects underlying human heart failure and may represent a novel therapeutic target.
We have identified two potential mechanisms for mtDNA depletion in the failing heart. We show that the mtDNA replication is severely impaired at the step of single strand DNA extension. This is associated with a downregulation in the expressions of all proteins involved in the replication fork. In addition, the oxidative DNA damage is increased more than 50% in the failing heart. Although it has been suggested that oxidative damage of mtDNA occurs at a much greater rate compared to nDNA 17, 27 we were unable to distinguish the oxidative damage of mtDNA from that of nDNA in this study. Nevertheless, a recent study has demonstrated that mitochondria-targeted antioxidants protect against mtDNA depletion and left ventricular remodeling post myocardial infarction in mice. 28 
PGC-1-Mediated Mitochondrial Biogenesis in Heart Failure
Recent studies have identified PGC-1 coactivated transcriptional mechanism as a master regulator of mitochondrial biogenesis in a variety of cell types including cardiac myocytes. 6, 8, 9, 29 In rodent models of heart failure decreased PGC-1␣ mRNA levels have been associated with impaired mitochondrial biogenesis and function, suggesting that downregulation of the PGC-1 pathway may lead to mitochondrial dysfunction and pathogenesis of heart failure. 6, 29 Two prior studies examining the PGC-1␣ levels in human failing hearts have found Ϸ30% decreases in PGC-1␣ mRNA levels or protein. 30, 31 Surprisingly, the present study shows that the expressions of all three members of the PGC-1 family are unaltered in human failing hearts. The discrepancy of the observations between animal models and human diseases can be multi-factorial, including but not limited to, the treatment of patients versus untreated animal models, the stage of diseases, and the uniqueness of human biology. For example, the majority of patients with end-stage heart failure are treated with catecholamines or phosphodiesterase inhibitors that are known to stimulate PGC-1␣ expression via cAMPmediated mechanisms. 5 Differences in the severity of heart failure as well as the lack of age-matched control group could partially contribute to the different findings between the previous and the present human study because the expression of PGC-1␣ declines with age. 32, 33 Importantly, these observations suggest that PGC-1␣ downregulation does not uniformly present in human heart failure. Consistent with this notion, a recent analysis of gene expression database of human heart failure also found a 36% increase of PGC-1␣ expression in the failing hearts. 34 These results indicate that impaired mitochondrial biogenesis in the end stage human failing heart can occur in the absence of PGC-1␣ downregulation.
Among the transcriptional regulators that PGC-1␣ coactivates, we have observed a decreased expression of ERR␣ but not that of PPAR␣ or NRF. The mRNA levels of genes that are regulated by ERR␣ are downregulated but not of those that are coregulated by both ERR␣ and PPAR␣. This is consistent with the prior report showing that downregulation of PGC-1␣ target genes in human failing hearts is associated with a higher level of PGC-1␣ but a lower level of ERR␣. 34 These observations further pinpoint the role of ERR␣mediated transcription in human heart failure although this does not necessarily exclude the possibility that further stimulation of the PGC-1 mechanism may sustain mitochondrial function in the failing hearts. It has been shown in a mouse model that deletion of PGC-1␣ accelerates the development of heart failure. 6 However, given the previous findings that overexpression of PGC-1␣ in the mouse heart causes cardiomyopathy 35, 36 restoration of the ERR␣ protein levels may be a more effective strategy targeting mitochondrial biogenesis via the PGC-1 pathway in human heart failure.
In summary, we have found that mitochondrial biogenesis is severely impaired in the human failing heart as evidenced by depletion of mtDNA, attributable to reduced mtDNA replication, and significant loss of mtDNA encoded proteins. These defects are independent of the downregulation of PGC-1 gene expression but are associated with decreased ERR␣ expression. Thus, our findings provide a basis for investigating novel mechanisms and therapeutic strategies for mitochondrial dysfunction in human heart failure. 
